Simulations Plus

Simulations Plus is a United States-based scientific software and consulting brand focused on computer modeling and simulation for the life-sciences sector. Its principal area of specialization is ADMET analysis: the study of how a drug is absorbed, distributed, metabolized, excreted, and potentially produces toxic effects. These characteristics are central to pharmaceutical research because they help scientists evaluate candidate compounds, prioritize experiments, assess development risks, and support decisions across the drug-development process. The company’s software is used primarily by pharmaceutical and biotechnology organizations, but its modeling capabilities also address adjacent sectors. The industries associated with its products and services include industrial chemicals, cosmetics, food ingredients, and herbicides. This gives the brand a position at the intersection of scientific computing, cheminformatics, pharmacokinetics, toxicology, and regulatory-oriented research rather than that of a general-purpose enterprise software vendor. Simulations Plus is associated with commercial software products including GastroPlus and ADMET Predictor. GastroPlus is designed for mechanistic modeling and simulation of drug absorption and related pharmacokinetic behavior. ADMET Predictor supports the estimation and analysis of ADMET properties from chemical structures and related data. Together, these offerings represent the company’s emphasis on using computational methods to reduce reliance on trial-and-error experimentation and to improve the interpretation of laboratory and clinical evidence. The business also expanded beyond software through its September 2014 acquisition of Cognigen Corporation. Cognigen provided clinical-trial data analysis and consulting services, adding a clinical and quantitative-services capability to Simulations Plus’s existing modeling portfolio. The transaction linked the company’s preclinical and mechanistic simulation activities with expertise in analyzing clinical data and supporting pharmaceutical development programs. The brand’s commercial identity is therefore built around specialized, research-intensive tools and services rather than mass-market software. Its customers are organizations that need scientifically validated models, analytical workflows, and technical expertise for decisions involving compound selection, formulation, pharmacokinetics, toxicology, and clinical development. Available reference material does not establish a complete current executive roster, ownership structure, headquarters detail, product launch chronology, or recent corporate news, so those fields are left unspecified where reliable information is not provided.

Simulations Plus developed as a specialized provider of computational tools for pharmaceutical and related scientific research. Its business centers on the premise that mathematical models and simulations can help researchers understand the behavior of chemical and drug candidates before, during, and after laboratory or clinical testing. The company’s principal technical domain is ADMET, an acronym covering absorption, distribution, metabolism, excretion, and toxicity. ADMET properties influence whether a compound can be developed successfully, how it should be formulated and dosed, and what safety questions require further investigation. Rather than operating as a broad horizontal software company, Simulations Plus serves research-intensive organizations with domain-specific applications. Its products address drug absorption, pharmacokinetics, predictive toxicology, and related areas of pharmaceutical modeling. The company also identifies industrial chemicals, cosmetics, food ingredients, and herbicides among the sectors for which its modeling and simulation software can be relevant. This diversified application base reflects the transferability of ADMET and chemical-property modeling methods across regulated industries. Two named offerings associated with the brand are GastroPlus and ADMET Predictor. GastroPlus is a simulation platform for modeling drug absorption and related pharmacokinetic behavior. ADMET Predictor is intended to predict ADMET-related properties from chemical information, supporting compound assessment and prioritization. The products are positioned as tools for scientists and development teams who need to combine experimental information with computational predictions. The company’s capabilities expanded in September 2014 when it acquired Cognigen Corporation. Cognigen was described as a provider of clinical-trial data analysis and consulting services. This acquisition was strategically significant because it added expertise in clinical data and quantitative consulting to Simulations Plus’s existing software-centered business. The combination connected modeling work performed during earlier stages of drug development with analysis of evidence generated in clinical studies. Publicly referenced company material also records adoption of its software by U.S. government agencies. The U.S. Food and Drug Administration licensed GastroPlus in 2007, and the U.S. Environmental Protection Agency licensed ADMET Predictor in 2008. These events demonstrated that the company’s products were used beyond commercial pharmaceutical organizations and had relevance to regulatory and public-sector scientific work. The available source material does not provide enough information to reconstruct a complete founding chronology, identify the founder, document every product generation, or describe the company’s current management and ownership in detail. It does, however, establish a consistent historical direction: Simulations Plus built a niche around scientific modeling software, broadened its sector reach through ADMET applications, and added clinical-trial analytics and consulting through the Cognigen acquisition.

1. 2014Acquisition of Cognigen Corporation

   Simulations Plus acquired Cognigen Corporation, adding clinical-trial data analysis and consulting capabilities to its modeling and simulation portfolio.

   Source
2. 2008EPA licenses ADMET Predictor

   The U.S. Environmental Protection Agency licensed ADMET Predictor for predictive chemical and ADMET-related analysis.
3. 2007FDA licenses GastroPlus

   The U.S. Food and Drug Administration licensed GastroPlus, documenting use of Simulations Plus software in a federal regulatory-science setting.

A specialist scientific-software and services provider for ADMET prediction, pharmacokinetic modeling, drug-development simulation, and clinical data analysis.

• GastroPlusDrug absorption and pharmacokinetic simulation software

  GastroPlus is a scientific modeling and simulation application associated with the analysis of drug absorption and pharmacokinetic behavior. It is intended to help researchers evaluate how compounds move through biological systems and to integrate computational analysis into pharmaceutical development and regulatory-science workflows. The product was licensed by the U.S. Food and Drug Administration in 2007.

• ADMET PredictorADMET prediction software

  ADMET Predictor is software for estimating absorption, distribution, metabolism, excretion, and toxicity-related properties from chemical information. It supports computational screening and prioritization of compounds and can be applied in pharmaceutical, chemical, agricultural, cosmetics, food-ingredient, and related research settings. The U.S. Environmental Protection Agency licensed the software in 2008.

• Cognigen servicesClinical-trial data analysis and consulting

  Cognigen contributed clinical-trial data analysis and consulting services to the Simulations Plus portfolio after its acquisition in September 2014. The capability complements preclinical modeling and simulation by supporting quantitative interpretation of clinical-development data.

• 2014Acquire Cognigen CorporationM&A

  Simulations Plus sought to broaden its specialized modeling business with clinical-trial data analysis and consulting capabilities.

  What changed. The company acquired Cognigen Corporation in September 2014.

  Aftermath. The acquisition expanded the brand’s scope from software for ADMET and drug-development simulation to include clinical quantitative analysis and consulting.

  Source

• 2014Simulations Plus acquires Cognigen Corporation

  Simulations Plus acquired Cognigen Corporation, a provider of clinical-trial data analysis and consulting services. The transaction broadened Simulations Plus’s offering beyond software for mechanistic and ADMET modeling into clinical quantitative analysis.

  M&A
  Source
• 2008U.S. EPA licenses ADMET Predictor

  The U.S. Environmental Protection Agency licensed Simulations Plus’s ADMET Predictor software, extending documented use of the company’s predictive modeling tools into a government environmental and chemical-assessment context.

  Other
• 2007U.S. FDA licenses GastroPlus

  The U.S. Food and Drug Administration licensed GastroPlus, highlighting use of the company’s drug-absorption and pharmacokinetic simulation technology within a regulatory-scientific environment.

  Other

1. Simulations Plus